Hypersplenism due to portal hypertension: Retrospective evaluation of 17 patients treated by splenic embolization  by Petermann, A. et al.
DO
H
R
s
2
diagnostic and Interventional Imaging (2012) 93,  30—36
RIGINAL ARTICLE / Gastrointestinal imaging
ypersplenism  due  to  portal  hypertension:
etrospective  evaluation  of  17  patients  treated  by
plenic  embolization
A.  Petermanna,∗, P.  Chabrota, L.  Cassagnesa,
E. Dumousseta,  A.  Alﬁdjaa,  C.  Gageanua,  A.  Ravela,
A.  Abergelb, L.  Boyera
a Department  of  Radiology  B,  Gabriel  Montpied  Hospital,  University  Hospitals  of
Clermont-Ferrand,  63000  Clermont-Ferrand,  France
b Department  of  Hepatogastroenterology,  Estaing  Hospital,  University  Hospitals  of
Clermont-Ferrand,  63000  Clermont-Ferrand,  France
KEYWORDS
Splenic  embolization;
Hypersplenism;
Portal  hypertension;
Efﬁcacy;
Complications;
Thrombocytopenia
Abstract
Purpose.  —  The  objective  of  this  retrospective  study  was  to  analyze  the  efﬁcacy  and  morbidity
associated  with  splenic  artery  embolization  for  hypersplenism  due  to  portal  hypertension  (PHT),
as a  function  of  the  volume  of  the  splenic  parenchyma  embolized  and  the  type  of  PHT  (due  to
intrahepatic  block  or  segmental  PHT).
Patients  and  methods.  —  This  study  retrospectively  included  17  patients  with  hypersplenism
secondary  to  PHT  (intrahepatic  block,  n  =  14;  segmental,  n  =  3)  treated  by  splenic  artery
embolization.  The  splenic  volume  embolized  was  estimated  by  computed  tomography  (CT)
one month  after  embolization.  A  clinical  assessment  and  platelet  count  took  place  at  7  days,
1 month  and  6  months  after  the  embolization.
Results.  —  In  the  group  with  PHT  due  to  intrahepatic  block,  the  mean  volume  of  embolized
splenic parenchyma  was  63%  of  the  initial  volume  (range:  30—95%).  Six  months  later,  the  platelet
level had  increased  by  an  average  of  232%.  All  patients  with  fewer  than  80,000  platelets/mL
at 6  months  had  an  embolization  volume  less  than  50%.  In  the  segmental  PHT  group,  the  mean
volume of  the  embolized  parenchyma  was  62%  of  the  initial  volume  (range:  20—95%),  bleeding
symptoms  had  disappeared  in  all  patients,  and  the  platelet  level  exceeded  80,000/mL.  Six
patients (6/17,  35%)  had  complications,  two  minor  and  four  major:  two  splenic  abscesses,  one
respiratory  distress  with  ascites,  and  one  pancreatitis  with  ascites.  Five  of  the  six  complications
were observed  in  patients  with  a  volume  of  embolized  splenic  parenchyma  more  than  70%.
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Conclusion.  —  Our  results  show  that  splenic  embolization  of  more  than  50%  of  the  parenchyma
is effective  in  the  treatment  of  hypersplenism  due  to  PHT,  but  that  when  the  embolized  volume
exceeds 70%,  the  procedure  is  associated  with  considerable  morbidity.
© 2011  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Table  1  Causes  of  portal  hypertension.
PHT  due  to  intrahepatic  block
9  cirrhosis  secondary  to  hepatitis-C  virus
3  alcoholic  cirrhoses
1 primary  biliary  cirrhosis
1  cirrhosis  secondary  to  cystic  ﬁbrosis
Segmental  PHT
1  mantle-cell  lymphoma
1  compression  of  the  splenic  vein  by  metastatic
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agents  were  divided  into  microparticles  alone  (from  250  to
1200   in  diameter,  beginning  with  the  smallest:  Bead  block®
TERUMO,  Embospheres® BIOSPHÈRE,  and  Ivalon®)  (n  =  9),Hypersplenism  is  deﬁned  as  increased  activity  of  the  spleen
leading  to  pancytopenia  that  especially  affects  platelets.
Thrombocytopenia  can  be  particularly  disabling  if  it  then
contraindicates  a  necessary  treatment  with  a  side  effect
of  reducing  the  number  of  blood  cells,  such  as  interferon
for  cirrhosis  secondary  to  hepatitis-C,  for  example,  or  if
it  is  accompanied  by  gastrointestinal  bleeding  from  the
rupture  of  esophageal  varices  (EV).  This  pancytopenia  can
be  diminished  by  reducing  the  volume  of  the  functional
splenic  parenchyma  [1].  The  immune  role  of  the  spleen  and
therefore  the  consequences  of  a  splenectomy  nonetheless
require  analysis  and  prudence  before  a  primary  splenec-
tomy.  An  alternative  to  this  surgery  is  the  reduction  of  the
splenic  parenchyma  by  embolization  of  the  splenic  artery
[2—4].  This  procedure  can  be  useful  for  patients  in  poor
general  condition  [5,6], or  at  high  risk  for  general  anes-
thesia  or  for  whom  peri-  or  postoperative  complications  are
likely.
The  principal  objective  of  our  study  was  to  deter-
mine  retrospectively  the  efﬁcacy  and  morbidity  of  splenic
embolization  in  the  treatment  of  hypersplenism  secondary
to  portal  hypertension  (PHT),  as  a  function  of  the  splenic  vol-
ume  embolized.  A  secondary  objective  was  to  analyze  these
results  as  a  function  of  the  cause  of  the  PHT  (intrahepatic
block  vs.  segmental  PHT).
Patients and methods
Patients
A  retrospective  study  of  the  interventional  radiology
register,  radiologic  reports,  PACS  (picture  archives  and
communication  systems)  and  medical  ﬁles  allowed  us  to
identify  17  patients  (mean  age:  61  years)  treated  by  splenic
embolization  for  disabling  hypersplenism  in  our  center  from
August  1999  through  October  2009.  The  PHT  was  secondary
to  intrahepatic  block  in  14  patients  (group  1)  and  to  segmen-
tal  PHT  in  three  (group  2);  Table  1  summarizes  the  causes  of
these  cases  of  PHT.
The  indications  of  parenchymal  reduction  for
nine  patients  were  thrombocytopenia  too  severe
(<  80,000  platelets/mL)  to  initiate  or  continue  chemother-
apy  (interferon  treatment  in  seven  out  of  9  cases);  three
cases  of  recurrent  gastrointestinal  bleeding,  two  with
severe  thrombocytopenia;  two  cases  to  prevent  threatened
rupture  of  EV,  both  with  severe  thrombocytopenia;  one  case
of  thrombocytopenia  contraindicating  heart  valve  surgery;
one  case  of  severe  pancytopenia;  and  one  complex  case  of
anemia  involving  hypersplenism  due  to  PHT.
The  splenic  embolization  was  preceded  by  a  morphologic
work-up  in  all  patients,  by  CT  with  injection  for  15  of  them,
and  by  ultrasound  for  two  (treated  in  1999  and  2002).
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tadenopathies
1  thrombosis  of  the  splenic  vein  with  pancreatitis
mbolization protocol
he  percutaneous  arterial  access,  performed  under  con-
iousness  sedation,  was  obtained  with  Seldinger’s  technique
4F  introducer),  which  allowed  overall  opaciﬁcation  of  the
orta  as  a  landmark.  The  celiac  trunk  and  the  splenic  artery
7]  were  selectively  catheterized  with  a  Cobra  C2  (TERUMO)
r  Mickelson® (MERIT  MEDICAL)  catheter.
For  the  patients  with  PHT  due  to  intrahepatic  block
group  1),  the  objective  of  the  embolization  was  to  correct
he  thrombocytopenia  by  shrinking  the  splenic  parenchyma:
he  catheterization  was  thus  distal  and  allowed  exclusion
f  the  branches  preferentially  intended  for  the  lower  pole
to  reduce  the  risk  of  subdiaphragmatic  abscess)  (Fig.  1).
 Progreat® (TERUMO)  or  Renegade® (BOSTON  SCIENTIFIC)
icrocatheter  was  used  in  three  patients.  The  embolizationigure 1. 2D splenic angiography, showing the microparticulate
mbolization of approximately 50% of the parenchyma, with a
icrocatheter. This ﬁgure demonstrates the difﬁculty of estimating
he percentage of parenchyma embolized during the procedure.
3 A.  Petermann  et  al.
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Figure 2. Contrast CT 1 month after embolization of 70% of the
splenic parenchyma, showing splenomegaly, with a vast ﬂuid density
mass, not enhanced by the contrast product injection (arrow), that
is, a large mass of splenic necrosis. The functional parenchyma is
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esorbable  gelatin  (Curaspon® CURA  MEDICAL)  (n  =  2),  a
ombination  of  both  (n  =  2),  another  combination  of  coils
Vortex® Boston  Scientiﬁc)  and  microparticles  (n  =  1),  and
nother  of  coils,  microparticles,  and  the  Amplatz® Occluder
AGA  Medical,  USA,  Plymouth)  (n  =  1).  The  objectives  in  the
atter  case  were  not  only  to  correct  the  thrombocytope-
ia  but  also  to  prevent  a  very  threatening  EV  rupture.  Very
articular  attention  was  paid  to  the  dorsal  artery  of  the  pan-
reas  to  avoid  any  potential  reﬂux  of  the  embolic  agents.
he  objective  was  to  obtain  a  parenchymal  reduction  of  50
o  70%,  evaluated  during  the  parenchymal  phase  of  2D  serial
rteriograms.
In  the  case  of  segmental  PHT  (group  2),  the  objective
f  embolization  for  two  patients,  rather  than  improving
he  platelet  count,  was  to  diminish  the  venous  collateral
irculation  from  the  splenic  network  and  thus  diminish
astro-intestinal  bleedings.  The  embolization  in  these  cases
as  thus  aimed  more  at  the  trunk.  Coils  were  used  in  one
rocedure  and  Amplatz® Occluder  and  resorbable  gelatin  in
he  other.
Analgesic  management  followed  routinely  and  com-
ined  class  II  or  III  analgesics,  sometimes  with  an
nti-inﬂammatory  agent.
ollow-up
he  postprocedure  follow-up  was  analyzed  retrospectively
rom  the  medical  and  radiologic  ﬁles.
The  laboratory  tests  included  a  blood  electrolyte  analy-
is  with  creatinine  levels  assayed  together  with  pancreatic
nzymes  (lipase)  before  discharge,  as  well  as  a  platelet
ount  at  7  days,  1  month  and  6  months.  Success  was  deﬁned
y  a  platelet  count  more  than  80,000  units/mL,  a  threshold
ecognized  as  less  disabling  [8].
Morphologic  veriﬁcation  by  CT  took  place  at  1  month,
erformed  by  experienced  vascular  radiologists.  The  volume
f  the  parenchyma  embolized  was  assessed  by  propagation
f  the  manual  contours  of  the  total  splenic  volume  and  the
ascularized  volume,  based  on  the  acquisition  of  the  por-
al  phase  after  the  contrast  product  injection  (Fig.  2).  The
xcluded  volume  was  expressed  as  a  percentage  of  the  initial
olume  according  to  the  formula:
V  necrotized  =  (V  total  —  V  vascularized)/V  total  ×  100
The  clinical  assessment  was  performed  by  the  patient’s
hysician,  at  discharge  and  at  consultations  at  1  month  and
 months.  Clinical  success  was  deﬁned  by  the  ability  to
esume  or  begin  a  treatment  that  induces  thrombopenia
such  as  interferon),  and  the  prevention  or  reduction  of
ecurrent  bleeding.
The  results  are  expressed  as  means  more  or  equal  to
tandard  deviations  and  compared  according  to  the  volume
f  embolized  parenchyma  and  the  cause  of  the  PHT.  The
mall  number  of  subjects  and  the  imbalance  between  the
wo  groups  make  any  statistical  analysis  impossible.
esultshe  mean  duration  of  follow-up  was  42  months  (range:
—122  months;  SD  ±  34  months).
The  mean  duration  of  hospitalization  was  8.6  days
2—37  days:  one  patient  with  cystic  ﬁbrosis  had
p
p
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mnhanced after injection (asterisk).
omplications  immediately  after  the  embolization  that
rolonged  her  hospital  stay).
The  embolization  procedure  was  a  technical  success  in
4%  of  cases.  We  intended  to  treat  18  patients  initially,  but
7  were  included  in  the  study;  splenic  catheterization  of  one
ould  not  be  performed  because  of  an  arched  ligament  and
mpassable  dysplastic  lesions.
In the  ﬁrst  group,  the  percentage  of  infarcted
arenchyma  varied  from  30  to  95%,  with  a  mean  of  63%:  ﬁve
mbolizations  produced  a  percentage  less  than  49%,  two  a
ercentage  from  50  to  69%,  and  the  other  eight  from  70  to
5%.
In  the  second  group,  embolization  led  to  a  mean  infarcted
olume  of  62%  (20—95%).
All  patients  experienced  a  transient  postembolization
yndrome  that  combined  abdominal  pain  and  fever.  The
ntensity  of  the  pain  resulted  in  emergency  imaging  for
ve  patients  (three  by  ultrasound  and  two  by  CT),  but  no
omplications  were  observed.  Transient,  relatively  modest,
eactive  left  pleural  effusion  was  observed  in  four  patients;
ll  tolerated  it  well,  with  symptomatic  treatment.
Overall,  we  counted  six  (33%)  complications,  two  minor
nd  four  major,  in  18  embolizations  (17  patients,  but  one
as  embolized  twice).  Table  2  summarizes  the  technical
haracteristics  of  these  procedures.
There  were  two  minor  complications  (11%):  one
symptomatic  thrombosis  of  the  splenic  vein  after  micropar-
iculate  embolization  of  80%  of  the  splenic  parenchyma;  and
ne  portal  vein  thrombosis  after  embolization  of  95%  of  the
arenchyma  by  microparticles  and  resorbable  gelatin  in  a
atient  with  hepatitis-C-induced  cirrhosis;  it  led  to  decom-
ensation  with  edema  and  ascites  that  resolved  rapidly  after
edical  treatment.
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Table  2  Complications  after  splenic  embolization.
Volume  of  embolization  (%)  Embolic  agent
Major  complications
Thrombosis  of  the  splenic  vein,  pancreatitis,  splenic
abscess
80  Microparticles  +  resorbable  gelatin
Splenic  abscess  35  Microparticles  +  coils
Respiratory  decompensation  and  ascite 75  Resorbable  gelatin
Thrombosis  of  the  splenic  vein,  ascites  with  edema,
and  pancreatitis
70 Microparticles
Minor  complications
Asymptomatic  thrombosis  of  the  splenic  vein  80  Microparticles
Portal  thrombosis,  and  decompensation  with  ascites,
rapidly  resolved
95 Microparticles  +  resorbable  gelatin
Four  patients  (22%)  had  major  complications:
• one  splenic  abscess,  discovered  2  months  after  emboliza-
tion  by  microparticles  and  coils  of  only  35%  of  the  splenic
parenchyma  in  a  patient  with  hepatitis-C-induced  cirrho-
sis;  a  splenectomy  followed  3  months  later  (Fig.  3);
• one  splenic  abscess,  drained  repeatedly,  developed  for
7  years  (surgery  was  contraindicated  by  the  patient’s
fragility),  associated  with  thrombosis  of  the  splenic
vein,  caudal  pancreatitis,  and  left  pleural  effusion;  the
complication  occurred  after  embolization  of  80%  of  the
splenic  parenchyma  by  microparticles  and  resorbable
gelatin,  again  in  a  patient  with  hepatitis-C-induced  cir-
rhosis.  The  embolization  was  performed  to  improve  his
thrombocytopenia  and  allow  him  to  undergo  a  cardiac
valvuloplasty;
• one  decompensation  with  edema  and  ascites,  associated
with  respiratory  decompensation,  after  embolization  of
75%  of  the  parenchyma  by  resorbable  gelatin  in  a  patient
Figure 3. CT injected at the portal phase 2 months after
embolization of 35% of the splenic parenchyma, demonstrating
a hypodense central-splenic mass (asterisk) in a severe septic
situation suggesting a splenic abscess. The needle biopsy and bac-
teriological analysis conﬁrmed the abscess.
with  cystic  ﬁbrosis;  she  ﬁnally  recovered  after  37  days  of
hospitalization  including  15  in  the  ICU;
• one  caudal  pancreatitis  (assessed  by  laboratory  tests  and
radiologic  imaging)  associated  with  thrombosis  of  the
splenic  vein,  which  led  to  decompensation  with  ascites;
this  complication  followed  microparticulate  embolization
of  70%  of  the  parenchyma.  The  clinical  course  improved
rapidly.
In  conclusion,  excluding  both  the  usual  postemboliza-
tion  syndrome,  which  can  be  controlled  with  analgesics,  and
low  levels  of  reactive  left  pleural  effusion,  11/17  patients
had  simple  recoveries  and  six  had  complications.  Five  of
these  complications  occurred  in  the  ten  procedures  that
embolized  a  volume  egal  or  more  than  70%.  That  is,  the
risk  of  complications  in  our  series  was  50%  when  the  per-
centage  of  parenchyma  embolized  exceeded  70%.  There  was
only  one  complication  for  the  eight  splenic  embolizations  of
a  volume  less  than  70%.  All  six  complications  took  place  in
group  1.  Table  3  compares  the  percentages  of  parenchyma
embolized  (mean  and  range)  according  to  the  presence  of
complications.
Table  4,  which  summarizes  the  embolization  agents,  the
parenchymal  volume  embolized,  and  the  platelet  changes,
shows  the  substantial  improvement  in  thrombocytopenia
after  splenic  embolization.  The  mean  increase  in  the
platelet  pool  at  6  months  in  group  1  was  232%,  and  it  ranged
from  —  8%  to  +  581%.
As  measured  by  clinical  and  laboratory  tests,  this  proce-
dure  was  thus  a success  for  15  (83%)  of  the  17  patients.  In  the
group  with  PHT  from  intrahepatic  block,  the  initial  objective
was  correction  of  thrombocytopenia.  Table  5  summarizes
Table  3  Mean,  percentage,  and  range  of  embolized
parenchymal  volume  in  the  groups  with  and  without
complications.
Mean  (%) Range  (%)
Group  A  72.5  35—95
Group  B 60.5 20—95
Group A: patients with complications; group B: patients without
complications.
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Table  4 Trends  in  platelet  counts  before  and  after  embolization,  with  calculation  of  the  percentage  variation  in  platelets  between  D0  and  6  months  (patients  one
to  14  are  group  1,  patients  15  to  17,  group  2).
Patient Volume  embolized  (%)  Embolization  agent  Platelet  count  (units/mL)  Platelet  variation  between
D0  and  6  months  as  a  %
Before  1  week  1  month  6  months
1  40  Microparticle  58,000  85,000  59,000  53,000  −8.6
2  66  Gelatin  18,000  156,000  125,000  88,000  388.9
3  95  Microparticle  50,000  127,000  288,000  113,000  126
4  80  Microparticle  +  gelatin  27,000  138,000  162,000  160,000  492.6
5  70  Microparticle  146,000  154,000  332,000  185,000  26.7
6  35  Microparticle  +  coils  16,000  37,000  81,000  68,000  325
7  30  Microparticle  54,000  126,000  191,000  143,000  164.8
8  95  Microparticle  29,000  49,000  160,000  105,000  262.1
9  80  Microparticle  22,000  260,000  200,000  150,000  581.8
10 70  Microparticle  28,000  109,000  145,000  417.9
11  30  Microparticle  64,000  88,000  37.5
11a 80  Microparticle  88,000  168,000  383,000  335.2
12  40  Amplatz  +  coil  +  gelatin  51,000  156,000  203,000  71,000  39.2
13  60  Microparticle  65,000  254,000  187,000  180,000  176.9
14  75  Gelatin  47,000  500,000  269,000  107,000  127.7
Mean  63.1  50,866.7  165,642.9  194,857.1  120,615.4  232.9
SD  22.7  33,357.1  115,201.2  95,499.4  43,335.0  184.1
Minimum  30.0  16,000.0  37,000.0  59,000.0  53,000.0  −8.6
Maximum  95.0  146,000.0  500,000.0  383,000.0  185,000.0  581.8
15  95  Coils  435,000  1,023,000  623,000  670,000
16  20  Amplatz  +  curaspon  110,000  254,000  162,000  DCD
17  70  Microparticle  +  gelatin  21,000  110,000  96,000  DCD
Mean  61.7  188,666.7  462,333.3  293,666.7  670,000.0
SD  38.2  217,922.8  490,860.8  287,113.8
Minimum  20.0  21,000.0  110,000.0  96,000.0  670,000.0
Maximum  95.0  435,000.0  1,023,000.0 623,000.0  670,000.0
a Second embolization at 2 months, due to insufﬁcient initial result.
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Table  5  Trends  in  the  platelet  count  as  a  function  of  the  threshold  of  80,000  platelets/mL,  before  and  after  embolization.
<  80,000  platelets/mL  >  80,000  platelets/mL
Before  procedure 13  2
1  week  after  embolization  2  12
1  patient  did  not  have  blood  count
1  month  after  embolization 1  13
1  patient  did  not  have  this  blood  count
6  months  after  embolization 3 10
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p2  patients  did  not  have  this  blood  count
the  trends  in  these  patients’  platelet  counts,  relative  to  the
value  of  80,000  platelets.
It shows  that  at  6  months,  10  patients  (71%)  continued
to  maintain  adequate  platelet  levels,  while  three  (21%)  had
fallen  once  again  below  the  threshold  of  80,000  platelets.
Among  those  three,  one  had  undergone  embolization  of
40%  of  the  splenic  parenchyma  by  microparticles  alone,  the
second  embolization  of  35%  of  the  splenic  parenchyma  by
microparticles  and  coils,  and  the  third  embolization  of  40%
by  the  Amplatz® Occluder  and  coils  and  resorbable  gelatin,
with  the  aim  of  correcting  the  thrombocytopenia  but  also
of  preventing  threatened  esophageal  variceal  hemorrhages.
One  patient  did  not  have  a  platelet  count  at  6  months.
One  patient  had  two  embolization  2  months  apart,  after
an  inadequate  response  to  the  ﬁrst  attempt.  This  patient
had  a  hepatocellular  carcinoma  (HCC)  measuring  6  cm  in
its  longest  dimension,  resulting  from  alcoholic  cirrhosis,
with  pancytopenia  most  marked  for  the  platelet  lineage
and  thus  contraindicating  chemical  embolization.  The  ﬁrst
embolization  by  microparticles  (500—700  m)  shrank  the
splenic  volume  by  30%;  the  platelet  count  rose  from  64,000
before  the  procedure  to  88,000  1  month  after  the  procedure.
The  medical  team  then  decided  on  a  second  embolization.
The  embolization  of  PHT  due  to  intra-hepatic  block  met
the  initial  objective  for  12/14  patients,  because  it  cor-
rects  thrombopenia  and  allowed  for  several  patients  to
begin  or  resume  interferon  treatment  or  chemotherapy
(platelet  levels  for  some  patients  did  not  increase  beyond
80,000/mL,  but  treatment  was  nonetheless  possible  thanks
to  the  improvement,  even  moderate,  of  their  thrombocy-
topenia).  In  the  woman  with  pancytopenia,  with  refractory
anemia  of  complex  origin,  not  only  did  her  thrombocytope-
nia  improve,  but  her  hemoglobin  level  rose  by  2  g/dL.
On  the  other  hand,  in  two  cases,  the  initial  objective  was
not  met:  the  patient  who  was  to  undergo  heart  surgery  could
not  because  the  splenic  abscess  developed,  became  chronic,
and  was  drained  repeatedly;  the  second  patient  also  devel-
oped  a  splenic  abscess,  which  contraindicated  the  initiation
of  interferon  therapy  to  treat  his  hepatitis-C-induced  cirrho-
sis.
The  objective  set  for  the  patients  with  segmental  PHT
was  met  in  all  cases  where  the  procedure  was  technically
possible.  In  two  patients  who  underwent  embolization  for
recurrent  gastro-intestinal  bleedings,  bleeding  symptoms
did  not  recur,  after  a  follow-up  of  16  months  for  one  and
4  months  (followed  by  death  from  another  cause)  in  the
other.
The  patient  with  an  embolization  for  pancytopenia
due  to  splenomegaly  associated  with  lymphoma  showed
t
i
olear  improvement  in  her  platelet  level,  which  rose  above
0,000/mL.
iscussion
addison  described  the  ﬁrst  splenic  parenchymal  emboliza-
ion  in  1973  [1],  reporting  the  case  of  a  man  with  cirrhosis
nd  thrombocytopenia  complicated  by  recurrent  gastroin-
estinal  bleeding  from  EV  ruptures.  He  was  successfully
reated  by  splenic  embolization.  Since  then,  several  studies
ave  shown  the  technical  feasibility  and  favorable  results  in
atients  with  cirrhosis  [8,9]  and  pointed  out  in  particular  its
ess  onerous  postoperative  course  than  that  for  surgery.  The
tudy  by  Koconis  et  al.  [10], a retrospective  review  of  the
nglish  language  literature  on  splenic  embolization  in  PHT,
lso  emphasized  the  good  results  of  this  technique.
With  clinical  success  for  15/17  (88%)  patients  in  our
eries,  splenic  embolization  appeared  effective  in  the  treat-
ent  of  hypersplenism  due  to  PHT,  regardless  of  cause,  and
n  particular  effective  in  the  correction  of  thrombocytope-
ia.
Consistent  with  the  data  in  the  literature,  the  efﬁcacy
f  splenic  embolization  for  thrombocytopenia  depended  on
hrinking  the  parenchymal  volume  by  at  least  50%:  Zhu  et  al.
9]  concluded  in  a  study  of  62  patients  that  infarction  must
over  at  least  50%  of  the  volume  for  the  platelet  count  to
ise  signiﬁcantly,  and  Noguchi  et  al.  [11]  reported  that  the
ncrease  in  the  platelet  pool  is  positively  correlated  with
he  size  of  the  splenic  infarction.  Hayashi  et  al.  [8]  reported
hat  the  infarction  volume  is  the  best  predictive  factor  of
he  platelet  increase,  with  a  cut-off  of  388  mL  of  infarction
o  obtain  an  increase  of  50,000  to  80,000  platelets/mL  at
 year.
In the  group  with  hypersplenism  due  to  segmental  PHT,  in
articular  due  to  thrombosis  or  compression  of  the  splenic
ein,  occlusion  most  proximal  to  the  splenic  artery,  to  dimin-
sh  collateral  circulation  from  the  splenic  network,  proved
fﬁcacious  in  all  cases,  with  the  disappearance  of  bleed-
ng  symptoms  and  a  higher  platelet  count.  Nonetheless  the
ize  of  our  population  was  very  limited.  The  study  by  Koconis
t  al.  [10]  conﬁrmed  the  efﬁcacy  reported  by  several  authors
f  splenic  embolization  in  the  treatment  of  gastrointesti-
al  bleeding  due  to  esophageal  variceal  rupture  in  cirrhotic
atients.Sometimes  severe  complications  (abscess,  decompensa-
ion,  either  respiratory  or  with  edema  and  ascites)  occurred
n  six  cases  (33%).  Five  of  them  involved  splenic  infarction
f  70%  or  more  of  the  parenchymal  volume,  independently
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f  the  type  of  embolic  agent  used.  These  observations  are
onsistent  with  those  of  Matsumoto,  N’Kontchou,  and  Zhu
t  al.  [9,12,13].  The  latter  found  that  the  complication
ate  increased  clearly  with  the  size  of  the  infarction  (0%  of
omplications  for  infarction  equal  or  less  than  50%,  8.8%  for
nfarction  from  50  to  70%,  and  50%  for  infarctions  equal  or
ore  than  70%).  Our  study  nonetheless  included  one  splenic
bscess  for  an  infarction  of  only  35%,  which  to  our  knowledge
as  not  previously  been  reported.
The  literature  treats  postembolization  syndrome  (pain  on
he  left  hypochondrial  region  and  fever)  and  reactive  left
leural  effusion  either  as  side  effects  [9,12—14]  or  as  minor
omplications  [2,4,6]. The  physiological  character  of  this
yndrome,  with  the  pain  linked  to  ischemia  and  the  fever
o  the  release  of  inﬂammation  mediators  by  the  necrotized
ells,  led  us  to  consider  it  as  a  side  effect,  especially  because
ppropriate  preventive  symptomatic  treatment  can  reduce
he  onset  of  these  symptoms.  This  syndrome  occurred  in
ll  of  our  patients,  but  with  variable  severity,  underlining
he  insufﬁcient  nature  of  our  preventive  treatment  after
mbolization.  The  reactive  left  pleural  effusion  is  due  in
art  to  the  respiratory  inhibition  associated  with  pain,  and
he  risk  of  its  onset  can  be  reduced,  according  to  Yoshida
t  al.  [4],  by  embolizing  the  lower  pole  or  middle  portion  of
he  spleen.
Zhu  et  al.  [15]  studied  embolization  agents  and  reported
hat  microparticles  were  more  efﬁcacious  than  resorbable
elatin  in  terms  of  the  platelet  and  white  cell  counts;  on
he  other  hand,  there  was  no  signiﬁcant  difference  in  the
ncidence  of  complications  in  the  two  groups.  The  number
f  patients  in  our  study  is  too  low  for  a  comparative  study
f  embolization  agents:  two  complications  for  nine  patients
ho  had  microparticles  alone  and  one  complication  for  two
ith  resorbable  gelatin  alone.  We  note  nonetheless  that  in
he  two  cases  where  we  used  microparticles  and  gelatin
ogether,  too  large  a  volume  was  embolized  (>  70%),  and
oth  cases  had  major  complications.
One  of  the  great  technical  difﬁculties  in  this  procedure
nvolves  the  quantiﬁcation  of  the  volume  infarcted  during
he  procedure  with  conventional  angiographic  series;  the
roduction  of  splenic  images  in  ‘‘CT-like’’  slices  by  the  most
ecent  angiography  systems  may  be  extremely  helpful  in  this
egard.
onclusion
onsistent  with  the  data  from  the  literature,  our  series
onﬁrmed  that  effective  splenic  artery  embolization  for
ypersplenism  due  to  PHT  requires  embolization  of  more
han  50%  of  the  parenchyma  and,  simultaneously,  that  the
omplication  rate  increases  substantially  when  more  than
0%  is  embolized.  The  assessment  of  the  parenchymal  vol-
me  embolized  during  the  procedure  remains  difﬁcult  in
linical  practice.  Moreover,  prospective  studies  are  neces-
ary  to  reﬁne  the  values  of  these  thresholds.
[A.  Petermann  et  al.
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